Maze Therapeutics, Inc. Common Stock (MAZE) Stock
Key stats
- Market cap
- $2.01B
- Price / Earnings ratio
- -12.8x
- EPS (TTM)
- -$2.60
- Volume
- Loading
- 52-week high
- $53.65
- 52-week low
- $21.95
Source: third-party data provider, as of November 13, 2026
Compare with MAZE
Recent news
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
MAZE
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
MAZE
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
MAZE
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
MAZENews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 73.85
- MACD 12/26/9
- 1.96
- EMA 9 of MACD
- 1.58
- MACD histogram
- 0.38
- SMA 50
- $28.33
- Price above SMA 50
- EMA 50
- $29.88
- Price above EMA 50
- SMA 200
- $31.46
- Price above SMA 200
- EMA 200
- $32.10
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
MAZEHow Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
MAZE3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
MAZEThe Surprise That Sent Vertex — And Its Chief Rival — Soaring
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
MAZE
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
MAZE
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
MAZE
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
MAZE
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
MAZE
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
MAZE
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
MAZENews tone: automated (AI) classification of the article's content, not a price prediction.
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | CEO & Director | 1976 |
| Mr. Misbah Tahir CPA | CFO & Principal Accounting Officer | 1975 |
| Dr. Harold S. Bernstein M.D., Ph.D. | President of Research & Development and Chief Medical Officer | 1960 |
| Mr. Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations | — |
| Ms. Courtney J. Phillips J.D. | General Counsel & Corporate Secretary | 1975 |
| Mr. Matt Krause | Senior Vice President of Human Resources | — |
| Mr. Atul Dandekar | Chief Strategy & Business Officer | 1972 |
| Ms. Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain | 1963 |
| Mr. Maarten Hoek | Senior Vice President of Research | — |
| Mr. Winston Tse | Senior Vice President of Drug Discovery | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 73.85
- MACD 12/26/9
- 1.96
- EMA 9 of MACD
- 1.58
- MACD histogram
- 0.38
- SMA 50
- $28.33
- Price above SMA 50
- EMA 50
- $29.88
- Price above EMA 50
- SMA 200
- $31.46
- Price above SMA 200
- EMA 200
- $32.10
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $46.00
- Average
- $63.50
- High
- $110.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.0 | -34.6 | -8.5 | -2.6 | +17.2 | -9.7 | -2.8 | +2.5 | +18.1 | +20.9 |
